Cogent Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cogent Biosciences, Inc. (COGT) on February 22, 2021. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change disclosed is the appointment of Todd E. Shegog as a Class II director, effective February 22, 2021. Mr. Shegog was also appointed as the Chair of the Audit Committee. He brings over 25 years of experience in financial, operations, corporate strategy, and compliance within the biotechnology and pharmaceutical sectors, having previously served as CFO for Forma Therapeutics, Synlogic, Inc., Forum Pharmaceuticals, Inc., and Millennium Pharmaceuticals, Inc.
Compensation and Contingencies
- Equity Compensation: Mr. Shegog will receive an option to purchase 37,500 shares of common stock, vesting over a three-year period from the grant date.
- Cash Compensation: He is entitled to $50,000 in annual cash compensation for his service on the Board and the Audit Committee.
- Indemnification: An indemnification agreement was entered into, under which the Company may be required to indemnify Mr. Shegog for expenses, including attorneys' fees, judgments, fines, and settlement amounts incurred in actions arising from his Board service.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 37,500 stock options granted to Todd E. Shegog.
- Confirm the total annual cash compensation obligation of $50,000 for the new director.
- Review the specific terms of the standard indemnification agreement to understand potential liability exposure.
- Check the composition of the Audit Committee to confirm Mr. Shegog's role as Chair.